Revolutionary Radiotherapy Technique Restores Swallowing Abilities for Head and Neck Cancer Patients
Results from a phase III clinical trial suggest that dysphagia-optimized intensity-modulated radiotherapy (DO-IMRT) could become the new gold standard for treating head and neck cancer patients. The trial compared DO-IMRT with standard intensity-modulated radiotherapy (IMRT) and found that DO-IMRT reduced the risk of swallowing difficulties without compromising treatment success. After two years, patients treated with DO-IMRT reported better swallowing function and higher normalcy of diet compared to those treated with IMRT. The tailored approach of DO-IMRT involves reducing radiation to the muscles involved in swallowing, which can help minimize side effects and improve patients' quality of life.